Skip to main content

Advertisement

SpringerLink
Log in

Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case–control study in North Indian population

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The epigenetic modifications have been reported to be key factors in breast carcinogenesis. In the current study, it has been tried to determine the methylation status of two tumour suppressor genes p14/ARF and p16/INK4a in 150 breast cancer patients as well as 150 controls by using MSP-PCR. There was, highly significant difference in methylation of p14/ARF and p16/INK4a (P = 0.000) between patients and controls. Methylation of both the genes together significantly increased the risk of breast cancer by 12.31 folds. The present study concludes that hypermethylation of p14/ARF and p16/INK4a promoters demonstrate significant association with the risk of breast cancer, hence indicating these as important tumour suppressor genes involved in the pathogenesis of breast cancer in North Indian population (i.e. Punjab, Haryana, Uttar Pradesh, Himachal Pradesh as well as Union Territory of Chandigarh).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 127:2893–2917

    Article  PubMed  CAS  Google Scholar 

  2. Agarwal G, Ramakant P (2008) Breast Cancer Care in India: the current scenario and the challenges for the future. Breast Care (Basel) 3:21–27

    Article  Google Scholar 

  3. Agarwal G, Ramakant P, Forgach ER et al (2009) Breast cancer care in developing countries. World J Surg 33:2069–2076

    Article  PubMed  Google Scholar 

  4. Worm J, Guldberg P (2002) DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 31:443–449

    Article  PubMed  CAS  Google Scholar 

  5. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229

    PubMed  CAS  Google Scholar 

  6. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, Jose-Eneriz ES, Cordeu L, Barrios M, Prosper F, Heiniger A, Torres A (2006) Promoter hyper methylation and global hypo methylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 20:1445–1448

    Article  PubMed  CAS  Google Scholar 

  7. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM (2004) p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 122:1284–1292

    Article  PubMed  CAS  Google Scholar 

  8. Lowe SW, Sherr CJ (2003) Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13:77–83

    Article  PubMed  CAS  Google Scholar 

  9. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000

    Article  PubMed  CAS  Google Scholar 

  10. Badal V, Menendez S, Coomber D, Lane DP (2008) Regulation of the p14ARF promoter by DNA methylation. Cell Cycle 7:112–119

    Article  PubMed  CAS  Google Scholar 

  11. Robertson KD, Jones PA (1998) The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18:6457–6473

    PubMed  CAS  Google Scholar 

  12. Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 12:5427–5440

    Article  Google Scholar 

  13. Kawamoto K, Enokida H, Gotanda T, Kubo H, Nishiyama K, Kawahara M, Nakagawa M (2006) p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 339:790–796

    Article  PubMed  CAS  Google Scholar 

  14. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevlier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannet NM, Sun K, Odum DT, Otte AP, Volkert TL, Bartel DP, Melton DA, Grifford DK, Jaenisch R, Young RA (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125:301–313

    Article  PubMed  CAS  Google Scholar 

  15. Ishida E, Nakamura M, Ikuta M, Shimada K, Matsuyoshi S, Kirita T, Konishi N (2005) Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol 41:614–622

    Article  PubMed  CAS  Google Scholar 

  16. Hsu HS, Wang YC, Tseng RC, Chang JW, Chen JT, Shih CM, Chen CY, Wang YC (2004) 5′ cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer. Clin Cancer Res 10:4734–4741

    Article  PubMed  CAS  Google Scholar 

  17. Xing EX, Nie Y, Song YL, Yang GY, Cai CC, Wang LD, Chung CS (1999) Mechanisms of inactivation of P14/ARF, P15/INK4b and P16INK4a genes in human esophageal squamous cell carcinoma: P14/ARF is potentially another inactivation hotspot within the 9p21 gene cluster. Clin Cancer Res 5:2704–2713

    PubMed  CAS  Google Scholar 

  18. Ding Y, Le XP, Zhang QX, Du P (2003) Methylation and mutation analysis of p16 gene in gastric cancer. World J Gastroenterol 9:423–426

    PubMed  CAS  Google Scholar 

  19. Elisei R, Shiohara M, Koeffler HP, Fagin JA (1998) Genetic and epigenetic alternations of the cyclin-dependent kinase inhibitors p15 INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83:2185–2193

    Article  PubMed  CAS  Google Scholar 

  20. Gazzeri S, Gouyer V, Vour’ch C, Brambilla C, Brambilla E (1998) Mechanisms of p16INK4A inactivation in non-small-cell lung cancers. Oncogene 16:497–504

    Article  PubMed  CAS  Google Scholar 

  21. Shim YH, Kang GH, Ro JY (2000) Correlation of p16 hyper methylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 80:689–695

    Article  PubMed  CAS  Google Scholar 

  22. Shim YH, Yoon GS, Choi HJ, Chung YH, Yu E (2003) p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 190:213–219

    Article  CAS  Google Scholar 

  23. Maeda K, Kawakami K, Ishida Y (2003) Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 10:935–938

    PubMed  CAS  Google Scholar 

  24. Murphy N, Heffronce CC, Ganguapati UG, Ring M, McGunin Ess E (2004) P16/INK4a positively in benign premalignant and malignant cervical glandular lesions. A potential diagnostic problem. Virchows Arch 445:610–615

    Article  PubMed  CAS  Google Scholar 

  25. Kimchi A (1998) DAP genes: novel apoptotic genes isolated by a functional approach to gene cloning. Biochim Biophys Acta 1377:F13–F33

    PubMed  CAS  Google Scholar 

  26. Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21:5380–5387

    Article  PubMed  CAS  Google Scholar 

  27. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826

    Article  PubMed  CAS  Google Scholar 

  28. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67–70

    PubMed  CAS  Google Scholar 

  29. Dominguez G, Silva J, Garcia JM et al (2003) Prevalence of aberrant methylation of P14/ARF over P16/INK4a in some human primary tumors. Mutat Res 530:9–17

    Article  PubMed  CAS  Google Scholar 

  30. Essel Dulaimi I, Robert G, Uzzo I, Richard E, Greenberg I, Tahseen A-S, Paul C (2004) Detection of bladder cancer in urine by tumour suppressor gene hyper methylation panel. Clin Cancer Res 10:1887–1893

    Article  PubMed  Google Scholar 

  31. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P (2001) Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 81:217–229

    Article  PubMed  CAS  Google Scholar 

  32. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, Ralhan R (2009) Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol 31:487–500

    PubMed  CAS  Google Scholar 

  33. Vallian S, Sedaghat M, Nassiri I, Frazmand A (2009) Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. Cancer Res Clin Oncol 135(8):991–996

    Article  CAS  Google Scholar 

  34. Bagadi SA, Prasad CP, Kaur J, Srivastava A, Prashad R, Gupta SD, Ralhan R (2008) Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sci 82:1288–1292

    Google Scholar 

  35. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624–628

    Google Scholar 

  36. Hinshelwood RA, Melki JR, Huschtscha LI, Paul C, Song JZ, Stirzaker C, Reddel RR, Clark SJ (2009) Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum Mol Genet 18:3098–3109

    Article  PubMed  CAS  Google Scholar 

  37. Krassenstein R, Sauter E, Dulaimi E et al (2004) Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10:28–32

    Article  PubMed  CAS  Google Scholar 

  38. Elenbaas B, Weinberg RA (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264:169–184

    Article  PubMed  CAS  Google Scholar 

  39. Raish M, Dhillon VS, Ahmad A, Ansari MA, Mudassar S, Shahid M, Batra V, Gupta P, Das BC, Shukla N, Husain SA (2009) Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol 2:264–270

    PubMed  Google Scholar 

  40. Dumitrescu RG, Marian C, Krishnan SS, Spear SL, Kallakury BV, Perry DJ, Convit JR, Seillier-Moiseiwitsch F, Yang Y, Freudenheim JL, Shields PG (2010) Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med 14:1468–1475

    Google Scholar 

  41. Zhao YF, Shen SP, Jiang JY, Geng H, Guo JG, Xie LP (2010) Methylation and expression of gene p16INK4a and RB in breast carcinoma. Zhonghua Bing Li Xue Za Zhi 39(6):377–381

    PubMed  CAS  Google Scholar 

  42. Zheng S, Ma X, Zhang L, Gunn L, Smith MT, Wiemels JL, Leung K, Buffler PA, Wiencke JK (2004) Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer Res 64:2000–2006

    Google Scholar 

  43. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S et al (2007) Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 16:740–746

    Google Scholar 

  44. Dumitrescu Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM (2001) FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98:3346–3351

    Article  Google Scholar 

Download references

Acknowledgments

We are indebted to the staff of PGIMER for providing the clinical samples.

Author information

Authors and Affiliations

  1. Department of Biotechnology, Panjab University, Chandigarh, India

    Marjan Askari, Ranbir Chander Sobti & Mohsen Nikbakht

  2. Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Mohsen Nikbakht

  3. Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Suresh C. Sharma

Authors
  1. Marjan Askari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ranbir Chander Sobti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohsen Nikbakht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suresh C. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ranbir Chander Sobti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Askari, M., Sobti, R.C., Nikbakht, M. et al. Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case–control study in North Indian population. Mol Biol Rep 40, 4921–4928 (2013). https://doi.org/10.1007/s11033-013-2592-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-013-2592-5

Keywords

Search

Navigation